Fishman J, Anderson S, Talbird SE, Dingli D. Analysis of costs per responder in US adults with a paroxysmal nocturnal hemoglobinuria with suboptimal response to prior eculizumab treatment. Hematol Rep. 2023 Oct 13;15(4):578-91. doi: 10.3390/hematolrep15040060
Wakefield JR, Myers K. Social cost benefit analysis for deep sea minerals mining. Mar Policy. 2016 Jun 22. doi: 10.1016/j.marpol.2016.06.018
Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep;25(5):257-63.